|
FAM172A expression based on
|
| Comparison | Statistical significance |
| Normal-vs-Primary | 1.08430000533843E-08 |
|
Note
Cancer stage information is not available for 2 samples.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Stage1 |
5.4770999957654E-08 |
| Normal-vs-Stage2 |
3.380700E-03 |
| Normal-vs-Stage3 |
7.36769999454268E-08 |
| Normal-vs-Stage4 |
6.2254999999567E-07 |
| Stage1-vs-Stage2 |
2.640400E-01 |
| Stage1-vs-Stage3 |
5.078600E-01 |
| Stage1-vs-Stage4 |
3.478600E-01 |
| Stage2-vs-Stage3 |
1.384960E-01 |
| Stage2-vs-Stage4 |
1.254190E-01 |
| Stage3-vs-Stage4 |
7.771400E-01 |
|
|
Note
Patient race information is not available for 92 samples and one samples from American Indians not included in the above plot.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Caucasian |
1.64790003864823E-09 |
| Normal-vs-AfricanAmerican |
7.224200E-02 |
| Normal-vs-Asian |
1.996780E-04 |
| Caucasian-vs-AfricanAmerican |
1.614400E-01 |
| Caucasian-vs-Asian |
2.590000E-01 |
| AfricanAmerican-vs-Asian |
4.580600E-01 |
|
|
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Male |
7.3274999956574E-08 |
| Normal-vs-Female |
7.81529999605013E-08 |
| Male-vs-Female |
4.379200E-01 |
|
|
Note
Seventeen samples from patient below 21 years not considered in above plot.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Age(21-40Yrs) |
2.99630000033524E-07 |
| Normal-vs-Age(41-60Yrs) |
4.2770999997277E-07 |
| Normal-vs-Age(61-80Yrs) |
5.59670000011003E-07 |
| Normal-vs-Age(81-100Yrs) |
8.831800E-02 |
| Age(21-40Yrs)-vs-Age(41-60Yrs) |
6.214600E-01 |
| Age(21-40Yrs)-vs-Age(61-80Yrs) |
7.470200E-01 |
| Age(21-40Yrs)-vs-Age(81-100Yrs) |
5.755600E-01 |
| Age(41-60Yrs)-vs-Age(61-80Yrs) |
4.422800E-01 |
| Age(41-60Yrs)-vs-Age(81-100Yrs) |
6.725200E-01 |
| Age(61-80Yrs)-vs-Age(81-100Yrs) |
4.856200E-01 |
|
|
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Classical-VS-Tall |
2.058000E-01 |
| Classical-VS-Follicular |
2.331400E-01 |
| Classical-VS-Other |
3.590400E-01 |
| Classical-VS-Normal |
8.78229999945468E-07 |
| Tall-VS-Follicular |
6.703400E-01 |
| Tall-VS-Other |
7.743600E-01 |
| Tall-VS-Normal |
1.77707999999832E-05 |
| Follicular-VS-Other |
6.351800E-01 |
| Follicular-VS-Normal |
3.18779999997076E-06 |
| Other-VS-Normal |
1.605930E-02 |
|
|
Note
Cancer in nearby lymph nodes cannot be measured (NX) in 50 samples.
| pathologic_N descriptions |
| N0 | No regional lymph node metastasis |
N1 | Metastases in 1 to 3 axillary lymph nodes |
| N2 | Metastases in 4 to 9 axillary lymph nodes |
N3 | Metastases in 10 or more axillary lymph nodes |
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-N0 |
1.56519999960913E-07 |
| Normal-vs-N1 |
8.05150000005028E-08 |
| N0-vs-N1 |
1.833250E-01 |
|
|
